Dash Bio has raised $18.0M in total across 2 funding rounds.
Dash Bio's investors include Kindred Capital VC, Swift Ventures, True Ventures, Mario Götze, Veeral Mehta, Nico Rosberg.
Dash Bio is a technology-driven company that builds a fully automated platform combining AI, robotics, and integrated software to transform clinical bioanalysis, a critical step in drug development. Their platform delivers bioanalytical testing for clinical trials up to 10 times faster than traditional methods while maintaining or improving assay quality and compliance with Good Laboratory Practice (GLP) standards. Dash Bio serves biopharmaceutical companies, including growth-stage biotech firms and large pharmaceutical companies, by accelerating the drug development process, reducing costs, and improving data reliability across preclinical and clinical trial stages[1][2][4][5].
Founded by a team with deep expertise in biotechnology, automation, and AI, Dash Bio’s leadership includes CEO Dave Johnson (formerly Chief Data and AI Officer at Moderna), COO Ander Tallett (with experience leading enterprise systems at Moderna and Resilience), and CSO Ely Porter (co-founder and CTO of Rootpath). The idea emerged from recognizing the bottlenecks in traditional bioanalysis workflows, which are often manual, slow, and error-prone. Early traction came from building a technology-first, fully integrated bioanalysis lab designed from the ground up to automate and accelerate the entire workflow, differentiating Dash Bio from legacy contract research organizations (CROs)[1][2][4].
Dash Bio rides the convergence of synthetic biology, automation, AI, and cloud software to address critical inefficiencies in drug development. The timing is crucial as biopharma increasingly demands faster, more reproducible, and cost-effective bioanalytical testing to keep pace with rapid innovation in therapeutics. Market forces such as rising R&D costs, demand for personalized medicine, and regulatory pressures favor automation and digital transformation. Dash Bio’s technology-first approach positions it as a catalyst for industry-wide change, potentially reshaping how bioanalysis is conducted and accelerating the delivery of new medicines to patients[1][3][4].
Looking ahead, Dash Bio aims to scale its automated clinical bioanalysis lab and expand its assay portfolio beyond ELISA, LC-MS, and qPCR to cover more modalities and services. The company plans to deepen integration of AI and automation across the drug development lifecycle, potentially addressing other bottlenecks beyond bioanalysis. As the biotech industry embraces digital transformation, Dash Bio’s influence is likely to grow, driving faster, more reliable drug development and setting new standards for technology-enabled bioanalysis[2][4]. Their success will depend on continued innovation, expanding customer adoption, and navigating regulatory landscapes while maintaining high-quality standards.
Dash Bio has raised $18.0M across 2 funding rounds. Most recently, it raised $11.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $11.0M Seed | Kindred Capital VC, Swift Ventures, True Ventures, Mario Götze, Veeral Mehta | |
| Oct 1, 2024 | $7.0M Seed | Kindred Capital VC, Swift Ventures, True Ventures, Mario Götze, Nico Rosberg, Veeral Mehta |
